Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
Phase 1 Recruiting
18 enrolled
PALANGI3
Phase 1 Completed
26 enrolled
LAMP-2
Phase 1 Recruiting
20 enrolled
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
Phase 1 Terminated
14 enrolled
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
Phase 1 Terminated
8 enrolled
Imatinib and Trametinib for KRAS-mutated Solid Tumor
Phase 1 Recruiting
10 enrolled
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
13 enrolled
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase 1 Completed
68 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
3 enrolled
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
Phase 1 Completed
35 enrolled
Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia
Phase 1 Completed
23 enrolled
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
Phase 1 Completed
28 enrolled
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Phase 1 Completed
3 enrolled
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase 1 Completed
12 enrolled
Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Phase 1 Completed
19 enrolled
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Phase 1 Completed
37 enrolled
Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors
Phase 1 Withdrawn
Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Phase 1 Completed
9 enrolled
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
9 enrolled
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Phase 1 Completed
17 enrolled 8 charts
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
Phase 1 Completed
11 enrolled
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
Phase 1 Completed
40 enrolled
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
18 enrolled
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
25 enrolled
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase 1 Completed
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Phase 1 Completed
65 enrolled
Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer
Phase 1 Completed
38 enrolled
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Phase 1 Completed
78 enrolled
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 1 Completed
21 enrolled
Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
Phase 1 Completed
45 enrolled
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Phase 1 Unknown
36 enrolled
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Phase 1 Completed
27 enrolled
RPGOG1
Phase 1 Completed
36 enrolled
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Phase 1 Completed
26 enrolled
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
Phase 1 Terminated
6 enrolled
Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
Phase 1 Terminated
19 enrolled
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
Phase 1 Completed
22 enrolled
Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer
Phase 1 Completed
18 enrolled